Download MendeleyLY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
Jones, B.E., Brown-Augsburger, P.L., Corbett, K.S., Westendorf, K., Davies, J., Cujec, T.P., Wiethoff, C.M., Blackbourne, J.L., Heinz, B.A., Foster, D., Higgs, R.E., Balasubramaniam, D., Wang, L., Bidshahri, R., Kraft, L., Hwang, Y., Zentelis, S., Jepson, K.R., Goya, R., Smith, M.A., Collins, D.W., Hinshaw, S.J., Tycho, S.A., Pellacani, D., Xiang, P., Muthuraman, K., Sobhanifar, S., Piper, M.H., Triana, F.J., Hendle, J., Pustilnik, A., Adams, A.C., Berens, S.J., Baric, R.S., Martinez, D.R., Cross, R.W., Geisbert, T.W., Borisevich, V., Abiona, O., Belli, H.M., de Vries, M., Mohamed, A., Dittmann, M., Samanovic, M., Mulligan, M.J., Goldsmith, J.A., Hsieh, C.L., Johnson, N.V., Wrapp, D., McLellan, J.S., Barnhart, B.C., Graham, B.S., Mascola, J.R., Hansen, C.L., Falconer, E.(2020) Biorxiv
- PubMed: 33024963
- DOI: https://doi.org/10.1101/2020.09.30.318972
- Primary Citation of Related Structures:
7L3N - PubMed Abstract:
SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection.
